Objectif Cancer is still one of the most common causes of death in Europe and any treatments to avoid or alleviate health risk associated with cancer bears the potential to significantly ameliorate the health of the European population. A major rationale in current cancer therapy is based on the understanding that virtually all cells in higher organisms posses a cellular suicide program referred to as apoptosis. Under physiological circumstances, apoptosis is induced as a developmental program or, more frequently, as a consequence of environmental insult. In the latter instance, apoptosis is probably the single most important tumor suppressor mechanism in mammals. Cancer therapy has long relied on empirically derived cytotoxic treatments that are now recognized as relatively unspecific ways to induce cell death, with a certain preference for cancer cells and rapidly proliferating cells. A major clinical problem, of considerable practical importance, is the development of resistance to cytotoxic cancer drugs. From our current perspective, resistance to cytotoxic cancer drugs can be largely explained by the development of resistance to apoptosis. To resolve this problem, the project will study the following key questions:1. What determines the selective apoptotic killing of tumor cells by anticancer agents?2. Which molecular alterations underlie the development of apoptosis resistance in tumor cells and how can these alterations be reversed by specific treatments? In order to develop new strategies for the diagnosis and new therapeutic approaches for the treatment of apoptosis-resistant tumors, the pathways triggering apoptosis in various cell types will be addressed by a detailed analysis of the signaling pathways in various human tissues. We also propose to study the role of various cellular genes and mutations in these genes for the execution of the apoptotic response. A particular aspect of the current program is the use of genome-wide approaches Champ scientifique natural sciencesbiological sciencesgeneticsmutationmedical and health sciencesclinical medicineoncologynatural sciencesbiological scienceszoologymammalogy Programme(s) FP5-HUMAN POTENTIAL - Programme for research, technological development and demonstration on "Improving the human research potential and the socio-economic knowledge base" (1998-2002) Thème(s) Data not available Appel à propositions Data not available Régime de financement NET - Research network contracts Coordinateur AUSTRIAN ACADEMY OF SCIENCES Contribution de l’UE Aucune donnée Adresse Rennweg 10 A - 6020 INNSBRUCK Autriche Voir sur la carte Coût total Aucune donnée Participants (5) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE France Contribution de l’UE Aucune donnée Adresse Route de Mende 1919 34293 MONTPELLIER Voir sur la carte Coût total Aucune donnée GERMAN CANCER RESEARCH CENTER Allemagne Contribution de l’UE Aucune donnée Adresse Im Neuenheimer Feld 280 69120 HEIDELBERG Voir sur la carte Coût total Aucune donnée KAROLINSKA INSTITUTE Suède Contribution de l’UE Aucune donnée Adresse Karolinska Hospital 171 76 STOCKHOLM Voir sur la carte Coût total Aucune donnée THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN HEREINAFTER TRINITY COLLEGE DUBLIN Irlande Contribution de l’UE Aucune donnée Adresse St James's Hospital, James's Street 8 DUBLIN Voir sur la carte Coût total Aucune donnée UNIVERSITAETSKLINIKUM CHARITE - MEDIZINISCHE FAKULTAET DER HUMBOLDT-UNIVERSITAET ZU BERLIN Allemagne Contribution de l’UE Aucune donnée Adresse Lindenberger Weg 80 13125 BERLIN Voir sur la carte Coût total Aucune donnée